In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review

Background: Burkholderia cepacia complex (BCC) is a group of multi-drug resistant (MDR) pathogens that are challenging to treat, especially in cystic fibrosis (CF) patients. Ceftazidime-avibactam is a promising antibiotic combination for treating BCC infections, but its efficacy requires further in...

Full description

Saved in:
Bibliographic Details
Main Authors: Abolfazl Rafati Zomorodi, Leila Ghanbari_Afra, Hossein Faridafshar, Seyed Nooreddin Faraji, Fatemeh Zarepour, Maryamosadat Mavaei, Mohammad Rahmanian
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:New Microbes and New Infections
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S205229752500040X
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849397964392366080
author Abolfazl Rafati Zomorodi
Leila Ghanbari_Afra
Hossein Faridafshar
Seyed Nooreddin Faraji
Fatemeh Zarepour
Maryamosadat Mavaei
Mohammad Rahmanian
author_facet Abolfazl Rafati Zomorodi
Leila Ghanbari_Afra
Hossein Faridafshar
Seyed Nooreddin Faraji
Fatemeh Zarepour
Maryamosadat Mavaei
Mohammad Rahmanian
author_sort Abolfazl Rafati Zomorodi
collection DOAJ
description Background: Burkholderia cepacia complex (BCC) is a group of multi-drug resistant (MDR) pathogens that are challenging to treat, especially in cystic fibrosis (CF) patients. Ceftazidime-avibactam is a promising antibiotic combination for treating BCC infections, but its efficacy requires further in vitro evaluation. Methods: This systematic review was conducted following the PRISMA guidelines to assess the in vitro susceptibility of BCC strains to ceftazidime-avibactam. We systematically searched PubMed, Web of Science, Scopus, and Embase databases. Inclusion criteria required original articles reporting on BCC susceptibility to ceftazidime-avibactam using standard antimicrobial susceptibility testing methods. Results: A total of 9 studies met the inclusion criteria. These studies were conducted between 2010 and 2024, with data from the USA, France, Germany, Belgium, and other countries. The studies used various methods, including agar dilution, broth microdilution, and disc diffusion. The minimum inhibitory concentration (MIC) range for ceftazidime-avibactam was found to vary, with the combination showing significantly improved susceptibility compared to ceftazidime alone. Conclusion: This systematic review demonstrates that ceftazidime-avibactam significantly enhances the susceptibility of BCC strains, supporting its potential as an effective therapeutic option for BCC infections in CF patients. Further clinical studies are needed to confirm these findings and guide treatment strategies.
format Article
id doaj-art-40cdb4c61d214b75b51e50ef169562ed
institution Kabale University
issn 2052-2975
language English
publishDate 2025-08-01
publisher Elsevier
record_format Article
series New Microbes and New Infections
spelling doaj-art-40cdb4c61d214b75b51e50ef169562ed2025-08-20T03:38:48ZengElsevierNew Microbes and New Infections2052-29752025-08-016610160110.1016/j.nmni.2025.101601In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic reviewAbolfazl Rafati Zomorodi0Leila Ghanbari_Afra1Hossein Faridafshar2Seyed Nooreddin Faraji3Fatemeh Zarepour4Maryamosadat Mavaei5Mohammad Rahmanian6Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranInstructor, Department of Medical Surgical Nursing, Faculty of Nursing, Qom University of Medical Sciences, Qom, IranDepartment of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran; Student Research Committee, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, IranDepartment of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, IranSchool of Medicine, Kashan University of Medical Sciences, Kashan, IranPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, IranStudent Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Corresponding author. SBUMS, Arabi Ave, Daneshjoo Blvd, Velenjak, Tehran, 19839-63113, Iran.Background: Burkholderia cepacia complex (BCC) is a group of multi-drug resistant (MDR) pathogens that are challenging to treat, especially in cystic fibrosis (CF) patients. Ceftazidime-avibactam is a promising antibiotic combination for treating BCC infections, but its efficacy requires further in vitro evaluation. Methods: This systematic review was conducted following the PRISMA guidelines to assess the in vitro susceptibility of BCC strains to ceftazidime-avibactam. We systematically searched PubMed, Web of Science, Scopus, and Embase databases. Inclusion criteria required original articles reporting on BCC susceptibility to ceftazidime-avibactam using standard antimicrobial susceptibility testing methods. Results: A total of 9 studies met the inclusion criteria. These studies were conducted between 2010 and 2024, with data from the USA, France, Germany, Belgium, and other countries. The studies used various methods, including agar dilution, broth microdilution, and disc diffusion. The minimum inhibitory concentration (MIC) range for ceftazidime-avibactam was found to vary, with the combination showing significantly improved susceptibility compared to ceftazidime alone. Conclusion: This systematic review demonstrates that ceftazidime-avibactam significantly enhances the susceptibility of BCC strains, supporting its potential as an effective therapeutic option for BCC infections in CF patients. Further clinical studies are needed to confirm these findings and guide treatment strategies.http://www.sciencedirect.com/science/article/pii/S205229752500040XBurkholderia cepaciaCeftazidime/avibactamCystic fibrosisRespiratory tract infectionsSystematic review
spellingShingle Abolfazl Rafati Zomorodi
Leila Ghanbari_Afra
Hossein Faridafshar
Seyed Nooreddin Faraji
Fatemeh Zarepour
Maryamosadat Mavaei
Mohammad Rahmanian
In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review
New Microbes and New Infections
Burkholderia cepacia
Ceftazidime/avibactam
Cystic fibrosis
Respiratory tract infections
Systematic review
title In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review
title_full In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review
title_fullStr In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review
title_full_unstemmed In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review
title_short In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review
title_sort in vitro susceptibility of burkholderia cepacia to ceftazidime avibactam a systematic review
topic Burkholderia cepacia
Ceftazidime/avibactam
Cystic fibrosis
Respiratory tract infections
Systematic review
url http://www.sciencedirect.com/science/article/pii/S205229752500040X
work_keys_str_mv AT abolfazlrafatizomorodi invitrosusceptibilityofburkholderiacepaciatoceftazidimeavibactamasystematicreview
AT leilaghanbariafra invitrosusceptibilityofburkholderiacepaciatoceftazidimeavibactamasystematicreview
AT hosseinfaridafshar invitrosusceptibilityofburkholderiacepaciatoceftazidimeavibactamasystematicreview
AT seyednooreddinfaraji invitrosusceptibilityofburkholderiacepaciatoceftazidimeavibactamasystematicreview
AT fatemehzarepour invitrosusceptibilityofburkholderiacepaciatoceftazidimeavibactamasystematicreview
AT maryamosadatmavaei invitrosusceptibilityofburkholderiacepaciatoceftazidimeavibactamasystematicreview
AT mohammadrahmanian invitrosusceptibilityofburkholderiacepaciatoceftazidimeavibactamasystematicreview